Equity · Healthcare
XERS
NASDAQXeris Biopharma Holdings (XERS)
The line runs 8 USD on 10 August through 15.18 USD on 6 November, on a scale from 5 to 20. Days the market did not trade hold the previous close, flat.
- Market cap
- 2.8B USD
- Revenue, year to Dec 2025
- 291.8M USD
- EPS, diluted, year to Dec 2025
- 0.00 USD
- 52-week range
- 5.28 USD – 15.18 USD
- Avg volume
- 225.7K
- Mentions, 30 days
- 12
- Net sentiment
- +0.06
as of Nov 6, 2026
Have Xeris Biopharma Holdings (XERS) insiders bought or sold shares recently?
In the 90 days to 8 Nov 2026, Xeris Biopharma Holdings insiders reported 12 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 11 Nov 2025, show no open-market purchase.
Form 4, 90 days to 8 Nov 2026, newest reported trade 5 Nov 2026
Buys 0Sells 12Net sold $1.72MOther filings 1
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 05 Nov 2026 | McCulloch KevinSee Remarks | Sell | 25,000 | 312K USD |
| 02 Nov 2026 | Hecht BethSee Remarks | Sell | 25,000 | 256K USD |
| 02 Nov 2026 | McCulloch KevinSee Remarks | Sell | 15,000 | 153K USD |
| 02 Nov 2026 | Pieper StevenSee Remarks | Sell | 5,000 | 51K USD |
| 01 Oct 2026 | Hecht BethSee Remarks | Sell | 16,666 | 157K USD |
| 01 Oct 2026 | McCulloch KevinSee Remarks | Sell | 15,000 | 141K USD |
| 01 Oct 2026 | Pieper StevenSee Remarks | Sell | 5,000 | 47K USD |
| 28 Sep 2026 | McCulloch KevinSee Remarks | Sell | 25,000 | 250K USD |
| 01 Sep 2026 | Hecht BethSee Remarks | Sell | 16,666 | 141K USD |
| 01 Sep 2026 | McCulloch KevinSee Remarks | Sell | 15,000 | 127K USD |
| 01 Sep 2026 | Pieper StevenSee Remarks | Sell | 5,000 | 43K USD |
| 12 Aug 2026 | Pieper StevenSee Remarks | Sell | 5,000 | 43K USD |
| Sold | 12 open-market sales | 173,332 | $1.72M |
1 other filing in the window: a grant, exercise, tax withholding or transfer, not a trade
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 02 Nov 2026 | Taddese MenassieDirector | Award | 22,365 |
Which funds hold Xeris Biopharma Holdings (XERS)?
8 of the 45 institutional funds we track reported a Xeris Biopharma Holdings position for the quarter ended 30 Jun 2026 — a combined 99.6M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| D. E. Shaw & Co. | Held (±25%) | 7,804,758 | 61.8M USD | +0.2% |
| Two Sigma Investments | Held (±25%) | 1,885,503 | 14.9M USD | −2.0% |
| AQR Capital Management | Held (±25%) | 1,540,985 | 12.2M USD | +10.5% |
| Citadel Advisors | Held (±25%) | 664,564 | 5.3M USD | −2.5% |
| Man Group | Added | 455,380 | 3.6M USD | +64.7% |
| Millennium Management | Trimmed | 131,664 | 1.0M USD | −94.2% |
| Renaissance Technologies | Trimmed | 67,337 | 533K USD | −85.1% |
| Tudor Investment Corp | Trimmed | 22,186 | 176K USD | −79.3% |
What has been filed or recorded for Xeris Biopharma Holdings (XERS)?
The filings we hold for Xeris Biopharma Holdings, newest first: 3 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 30 Sep 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 30 Sep 2026 | Fails to deliver | Shares failed to deliver | 209,157 shares | 2.1M USD notional · 0.115% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS 0.06 USD | |
| 30 Sep 2026 | Financials | Total assets | 423.2M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 48.8M USD | at period end |
| 29 Sep 2026 | Fails to deliver | Shares failed to deliver | 14,179 shares | 139K USD notional · 0.008% of shares out |
| 23 Sep 2026 | Fails to deliver | Shares failed to deliver | 106 shares | 925 USD notional · <0.001% of shares out |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.18 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS 0.01 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS 0.00 USD | |
| 31 Dec 2025 | Financials | Revenue | 291.8M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | 554K USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | 0.00 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS 0.00 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.01 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.06 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −0.37 USD |
What is Reddit saying about Xeris Biopharma Holdings (XERS)?
Reddit mentioned XERS 12 times in the 30 days to 7 November 2026, across 5 of the communities we track. All of them were scored for sentiment: 58% read bullish, 25% bearish and 17% neither. Reddit data updated 7 November 2026.
30-day window, Method
Mentions, 30 days 12Bullish 58%Bearish 25%Communities 5Against the market +4 points
How do Reddit mentions of Xeris Biopharma Holdings (XERS) compare with its price?
Share ↗
Where Xeris Biopharma Holdings (XERS) is discussed
30 days
| Community | Share | Mentions | Net sentiment |
|---|---|---|---|
| r/wallstreetbets | 50% | 6 | +0.04 |
| r/ausfinance | 25% | 3 | +0.02 |
| r/asx_bets | 8% | 1 | +0.18 |
| r/investing | 8% | 1 | +0.14 |
| r/stocks | 8% | 1 | +0.04 |
Moves with Xeris Biopharma Holdings (XERS)
Tickers whose daily Reddit volume rose and fell with Xeris Biopharma Holdings (XERS)'s. Co-discussion, not price.
AAL +0.59BRITISH POUND +0.57RPO +0.52FZILX +0.52UK −0.51HALL +0.50
How closely daily Reddit mention counts rose and fell together over the last 30 days (31 daily observations), Method
Xeris Biopharma Holdings (XERS): frequently asked questions
What did Xeris Biopharma Holdings shares close at?
Xeris Biopharma Holdings closed at 15.18 USD on 6 Nov 2026, up 15.92% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Xeris Biopharma Holdings’ market cap?
Xeris Biopharma Holdings is worth 2.8B USD by market value as of 6 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Xeris Biopharma Holdings’ revenue?
Xeris Biopharma Holdings reported revenue of 291.8M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Xeris Biopharma Holdings insiders bought or sold shares recently?
In the 90 days to 8 Nov 2026, Xeris Biopharma Holdings insiders reported 12 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 11 Nov 2025, show no open-market purchase. A further 1 filing was a grant, award, gift or exercise rather than an open-market trade. See Insiders
Which funds own Xeris Biopharma Holdings?
8 of the 45 funds we track reported a Xeris Biopharma Holdings position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were D. E. Shaw & Co., Two Sigma Investments and AQR Capital Management. See Funds
When did Xeris Biopharma Holdings last report earnings?
Xeris Biopharma Holdings last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of 0.06 USD; no next date is announced in SEC filings yet. See Filings
What is Reddit saying about Xeris Biopharma Holdings?
Xeris Biopharma Holdings was mentioned 3 times in the last 7 days across the finance subreddits we track, and 12 times over the trailing 30 days. Of the 12 mentions scored for sentiment, 58% read bullish and 25% bearish. That is a social signal, not investment advice. See Reddit
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- RedditReddit ingest across the tracked finance subreddits
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings